Cell-of-Origin (COO) Classification, BCL2 and MYC Expression Associated Outcome in Younger Patients Treated By RCHOP Front-Line Therapy Versus Intensive Regimen Followed By Autologous Transplant for De Novo Advanced Diffuse Large B Cell Lymphoma (DLBCL) : Results of the French Prospective Multicenter Randomized Trial Goelams-075 - Archive ouverte HAL Access content directly
Conference Poster Year : 2015

Cell-of-Origin (COO) Classification, BCL2 and MYC Expression Associated Outcome in Younger Patients Treated By RCHOP Front-Line Therapy Versus Intensive Regimen Followed By Autologous Transplant for De Novo Advanced Diffuse Large B Cell Lymphoma (DLBCL) : Results of the French Prospective Multicenter Randomized Trial Goelams-075

(1) , (1) , (1) , (1) , (2) , (3) , (4, 5) , (6) , (7) , (8) , (9) , (10) , (11, 12) , (13) , (14, 15) , (16) , (17) , (18) , (19) , (20, 21) , (2) , (22, 23, 24) , (25, 26) , (26) , (27, 26) , (28)
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
Jerome Cornillon
Gandhi Damaj
  • Function : Author
Eric Deconinck
Anne Banos
  • Function : Author
Anne Moreau
  • Function : Author
  • PersonId : 1202589
Thierry Fest
Noel Milpied
  • Function : Author
  • PersonId : 892874

Abstract

The prognostic value of COO classification by immunohistochemistry (IHC) for de novo untreated advanced DLBCL remains controversial after Rituximab-based frontline therapy. Other biomarkers such as BCL2 or MYC protein expression have been proposed to predict survival. IHC characteristics were investigated in a large multicenter randomized study.
Fichier principal
Vignette du fichier
Abstract ASH IHC GOELAMS075-full.pdf (640.27 Ko) Télécharger le fichier
Origin : Files produced by the author(s)

Dates and versions

hal-01290432 , version 1 (24-05-2017)

Identifiers

  • HAL Id : hal-01290432 , version 1

Cite

Gaëlle Laboure, Marie-Cecile Parrens, Anjarasoa Tsaranazy, Magali Bordier, Steven Le Gouill, et al.. Cell-of-Origin (COO) Classification, BCL2 and MYC Expression Associated Outcome in Younger Patients Treated By RCHOP Front-Line Therapy Versus Intensive Regimen Followed By Autologous Transplant for De Novo Advanced Diffuse Large B Cell Lymphoma (DLBCL) : Results of the French Prospective Multicenter Randomized Trial Goelams-075. 55th Annual Meeting and Exposition of the American-Society-of-Hematology, Dec 2013, La Nouvelle Orléans, United States. 126 (23), pp.3920, 2015. ⟨hal-01290432⟩
624 View
118 Download

Share

Gmail Facebook Twitter LinkedIn More